Q1: 2026-05-05 Earnings Summary
EPS of -$0.90 beats by $0.18
|
Revenue of
$141.00K
(95.83% Y/Y)
beats by $113.25K
Viridian Therapeutics, Inc. (VRDN) Discusses Positive Top Line Results From REVEAL-2 Phase III Trial in Chronic Thyroid Eye Disease May 5, 2026 8:00 AM EDT
Company Participants
Greg Rossino
Stephen Mahoney - CEO, President & Director
Radhika Tripuraneni - Chief Medical Officer
Anthony Casciano - Chief Commercial Officer
Shan Wu - Chief Business Officer
Conference Call Participants
Faisal Khurshid - Jefferies LLC, Research Division
Nathanael Charoensook - Leerink Partners LLC, Research Division
Laura Chico - Wedbush Securities Inc., Research Division
Rami Katkhuda - LifeSci Capital, LLC, Research Division
Michael Yee - UBS Investment Bank, Research Division
Joseph Thome - TD Cowen, Research Division
Anish Nikhanj - Truist Securities, Inc., Research Division
Douglas Tsao - H.C. Wainwright & Co, LLC, Research Division
Alexander Thompson - Stifel, Nicolaus & Company, Incorporated, Research Division
Jin Law - Goldman Sachs Group, Inc., Research Division
Lachlan Hanbury-Brown - William Blair & Company L.L.C., Research Division
Jacob Goell - Wells Fargo Securities, LLC, Research Division
Brandon Frith - Wolfe Research, LLC
Presentation
Operator
Good morning, ladies and gentlemen, and welcome to the Viridian Therapeutics conference call to review top line results from the REVEAL-2 Phase III clinical trial in chronic thyroid eye disease. [Operator Instructions] As a reminder, this conference call is being recorded.
I will now hand the call over to Greg Rossino, Senior Director of Investor Relations at Viridian. Please go ahead.
Greg Rossino
Thank you, Franz, and good morning, everyone. Thank you for joining us on our conference call to discuss the top line results from REVEAL-2, our Phase III clinical trial of elegrobart in patients with chronic thyroid eye disease. You can access the press release and slides for today's call on the Investors page of our corporate website at viridiantherapeutics.com.
Before we begin, I would like to remind everyone that this conference call and webcast will contain certain forward-looking statements. These statements are subject to risks
此内容由惯性聚合(RSS阅读器)自动聚合整理，仅供阅读参考。 原文来自 — 版权归原作者所有。